Biomarkers and manifestations of nuromyelitis optica spectrum disorder in an Argentinian population

Takeaway

  • This registry study found that 27.7% of aquaporin-4-antibody (AQP4-ab)-negative Argentinian individuals with neuromyelitis optica spectrum disorder (NMOSD) tested positive for myelin oligodendrocyte glycoprotein antibodies (MOG-ab), in line with results from other world regions.

Why this matters

    This is the first Argentinian NMOSD registry to study the percentage of patients in Latin America who have MOG-ab associated disease (MOGAD) and are AQP4-ab-neagtive.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.